Maybe let's see what the investigation shows.
This is the list of banned substances:
Substances Prohibited At All TimesIf a Substance or Method is not defined in this list, please verify with your Anti-Doping Organization.
S0. Non-Approved Substances
Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.
S1. Anabolic Agents
Anabolic agents are prohibited.
1. Anabolic Androgenic Steroids (AAS)
a. Exogenous* AAS, including:
1-androstenediol (5α-androst-1-ene-3β,17β-diol)
1-androstenedione (5α-androst-1-ene-3,17-dione)
1-testosterone (17β-hydroxy-5α-androst-1-en-3-one)
4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one)
19-norandrostenedione (estr-4-ene-3,17-dione)
bolandiol (estr-4-ene-3β,17β-diol)
bolasterone
boldenone
boldione (androsta-1,4-diene-3,17-dione)
calusterone
clostebol
danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol)
dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)
desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol)
drostanolone
ethylestrenol (19-norpregna-4-en-17α-ol)
fluoxymesterone
formebolone
furazabol (17α-methyl[1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol)
gestrinone
mestanolone
mesterolone
metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)
metenolone
methandriol
methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one)
methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one)
methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one)
methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one)
methyltestosterone
metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one)
mibolerone
nandrolone
norboletone
norclostebol
norethandrolone
oxabolone
oxandrolone
oxymesterone
oxymetholone
prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5α-androstane)
quinbolone
stanozolol
stenbolone
tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one)
trenbolone (17β-hydroxyestr-4,9,11-trien-3-one)
and other substances with a similar chemical structure or similar biological effect(s).
b. Endogenous** AAS when administered exogenously:
androstenediol (androst-5-ene-3β,17β-diol)
androstenedione (androst-4-ene-3,17-dione)
dihydrotestosterone (17β-hydroxy-5α-androstan-3-one)
prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one)
testosterone
and their metabolites and isomers, including but not limited to:
3β-hydroxy-5α-androstan-17-one
4-androstenediol (androst-4-ene-3β,17β-diol)
5-androstenedione (androst-5-ene-3,17-dione)
5α-androstane-3α,17α-diol
5α-androstane-3α,17β-diol
5α-androstane-3β,17α-diol
5α-androstane-3β,17β-diol
5β-androstane-3α,17β-diol
7α-hydroxy-DHEA
7β-hydroxy-DHEA
7-keto-DHEA
19-norandrosterone
19-noretiocholanolone
androst-4-ene-3α,17α-diol
androst-4-ene-3α,17β-diol
androst-4-ene-3β,17α-diol
androst-5-ene-3α,17α-diol
androst-5-ene-3α,17β-diol
androst-5-ene-3β,17α-diol
androsterone
epi-dihydrotestosterone
epitestosterone
etiocholanolone
2. Other Anabolic Agents, including but not limited to:
clenbuterol
selective androgen receptor modulators (SARMs, e.g. andarine and ostarine)
tibolone
zeranol
zilpaterol.
For purposes of this section: * “exogenous” refers to a substance which is not ordinarily produced by the body naturally. ** “endogenous” refers to a substance which is ordinarily produced by the body naturally.
Notes
For purposes of this section:
* “exogenous” refers to a substance which is not ordinarily produced by the body naturally.
** “endogenous” refers to a substance which is ordinarily produced by the body naturally.
S2. Peptide Hormones, Growth Factors, Related Substances and mimetics
The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:
1. Erythropoietin-Receptor agonists:
1.1 Erythropoiesis-Stimulating Agents (ESAs) including e.g.
darbepoietin (dEPO)
erythropoietins (EPO)
EPO-Fc
EPO-mimetic peptides (EMP) e.g.
CNTO 530
peginesatide
methoxy polyethylene glycol-epoetin beta (CERA).
1.2 Non-erythropoietic EPO-Receptor agonists, e.g.
ARA-290
asialo EPO
carbamylated EPO.
2. Hypoxia-inducible factor (HIF)
HIF stabilizers e.g.
cobalt
FG-4592
HIF activators e.g.
argon
xenon
3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors in males, e.g.
buserelin
gonadorelin
leuprorelin
4. Corticotrophins and their releasing factors, e.g.
corticorelin
5. Growth Hormone (GH) and its releasing factors including:
Growth Hormone Releasing Hormone (GHRH) and its analogues e.g.
CJC-1295
sermorelin
tesamorelin
Growth Hormone Secretagogues (GHS) e.g.
ghrelin
ghrelin mimetics e.g.
anamorelin
ipamorelin
GH-Releasing Peptides (GHRPs) e.g.
alexamorelin
GHRP-6
hexarelin
pralmorelin (GHRP-2).
Additional prohibited growth factors:
Fibroblast Growth Factors (FGFs);
Hepatocyte Growth Factor (HGF);
Insulin-like Growth Factor-1 (IGF-1) and its analogues;
Mechano Growth Factors (MGFs);
Platelet-Derived Growth Factor (PDGF);
Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.
S3. Beta-2 Agonists
All beta-2 agonists, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Except:
Inhaled salbutamol (maximum 1600 micrograms over 24 hours);
Inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours); and
Inhaled salmeterol in accordance with the manufacturers’ recommended therapeutic regimen.
The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.
S4. Hormone and Metabolic Modulators
The following hormone and metabolic modulators are prohibited:
1. Aromatase inhibitors including, but not limited to:
4-androstene-3,6,17 trione (6-oxo)
aminoglutethimide
anastrozole
androsta-1,4,6-triene-3,17-dione (androstatrienedione)
exemestane
formestane
letrozole
testolactone.
2. Selective estrogen receptor modulators (SERMs) including, but not limited to:
raloxifene
tamoxifen
toremifene.
3. Other anti-estrogenic substances including, but not limited to:
clomiphene
cyclofenil
fulvestrant.
4. Agents modifying myostatin function(s) including, but not limited, to:
myostatin inhibitors.
5. Metabolic modulators:
Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists e.g. GW 1516
Insulins and insulin-mimetics
Meldonium
Trimetazidine
S5. Diuretics and Masking Agents
The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).
Including, but not limited to:
desmopressin
probenecid
plasma expanders e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol
acetazolamide
amiloride
bumetanide
canrenone
chlortalidone
etacrynic acid
furosemide
indapamide
metolazone
spironolactone
thiazides, e.g. bendroflumethiazide
chlorothiazide and hydrochlorothiazide
triamterene
vaptans, e.g. tolvaptan.
Except:
drospirenone
pamabrom
ophthalmic use of carbonic anhydrase inhibitors, e.g.
brinzolamide
dorzolamide
Local administration of felypressin in dental anaesthesia.
The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding unless the Athlete has an approved TUE for that substance in addition to the one granted for the diuretic or masking agent.Hide
If a Substance or Method is not found, please verify with your Anti-Doping Organization to ensure that this Substance or Method is not prohibited as a related Substance or Method that falls under an existing category.
In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3.
Substances Prohibited In-CompetitionIf a Substance or Method is not defined in this list, please verify with your Anti-Doping Organization.
Expand All Collapse All
S0. Non-Approved Substances
Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.
S1. Anabolic Agents
Anabolic agents are prohibited.
1. Anabolic Androgenic Steroids (AAS)
a. Exogenous* AAS, including:
1-androstenediol (5α-androst-1-ene-3β,17β-diol)
1-androstenedione (5α-androst-1-ene-3,17-dione)
1-testosterone (17β-hydroxy-5α-androst-1-en-3-one)
4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one)
19-norandrostenedione (estr-4-ene-3,17-dione)
bolandiol (estr-4-ene-3β,17β-diol)
bolasterone
boldenone
boldione (androsta-1,4-diene-3,17-dione)
calusterone
clostebol
danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol)
dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)
desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol)
drostanolone
ethylestrenol (19-norpregna-4-en-17α-ol)
fluoxymesterone
formebolone
furazabol (17α-methyl[1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol)
gestrinone
mestanolone
mesterolone
metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)
metenolone
methandriol
methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one)
methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one)
methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one)
methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one)
methyltestosterone
metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one)
mibolerone
nandrolone
norboletone
norclostebol
norethandrolone
oxabolone
oxandrolone
oxymesterone
oxymetholone
prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5α-androstane)
quinbolone
stanozolol
stenbolone
tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one)
trenbolone (17β-hydroxyestr-4,9,11-trien-3-one)
and other substances with a similar chemical structure or similar biological effect(s).
b. Endogenous** AAS when administered exogenously:
androstenediol (androst-5-ene-3β,17β-diol)
androstenedione (androst-4-ene-3,17-dione)
dihydrotestosterone (17β-hydroxy-5α-androstan-3-one)
prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one)
testosterone
and their metabolites and isomers, including but not limited to:
3β-hydroxy-5α-androstan-17-one
4-androstenediol (androst-4-ene-3β,17β-diol)
5-androstenedione (androst-5-ene-3,17-dione)
5α-androstane-3α,17α-diol
5α-androstane-3α,17β-diol
5α-androstane-3β,17α-diol
5α-androstane-3β,17β-diol
5β-androstane-3α,17β-diol
7α-hydroxy-DHEA
7β-hydroxy-DHEA
7-keto-DHEA
19-norandrosterone
19-noretiocholanolone
androst-4-ene-3α,17α-diol
androst-4-ene-3α,17β-diol
androst-4-ene-3β,17α-diol
androst-5-ene-3α,17α-diol
androst-5-ene-3α,17β-diol
androst-5-ene-3β,17α-diol
androsterone
epi-dihydrotestosterone
epitestosterone
etiocholanolone
2. Other Anabolic Agents, including but not limited to:
clenbuterol
selective androgen receptor modulators (SARMs, e.g. andarine and ostarine)
tibolone
zeranol
zilpaterol.
For purposes of this section: * “exogenous” refers to a substance which is not ordinarily produced by the body naturally. ** “endogenous” refers to a substance which is ordinarily produced by the body naturally.
Notes
For purposes of this section:
* “exogenous” refers to a substance which is not ordinarily produced by the body naturally.
** “endogenous” refers to a substance which is ordinarily produced by the body naturally.
S2. Peptide Hormones, Growth Factors, Related Substances and mimetics
The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:
1. Erythropoietin-Receptor agonists:
1.1 Erythropoiesis-Stimulating Agents (ESAs) including e.g.
darbepoietin (dEPO)
erythropoietins (EPO)
EPO-Fc
EPO-mimetic peptides (EMP) e.g.
CNTO 530
peginesatide
methoxy polyethylene glycol-epoetin beta (CERA).
1.2 Non-erythropoietic EPO-Receptor agonists, e.g.
ARA-290
asialo EPO
carbamylated EPO.
2. Hypoxia-inducible factor (HIF)
HIF stabilizers e.g.
cobalt
FG-4592
HIF activators e.g.
argon
xenon
3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors in males, e.g.
buserelin
gonadorelin
leuprorelin
4. Corticotrophins and their releasing factors, e.g.
corticorelin
5. Growth Hormone (GH) and its releasing factors including:
Growth Hormone Releasing Hormone (GHRH) and its analogues e.g.
CJC-1295
sermorelin
tesamorelin
Growth Hormone Secretagogues (GHS) e.g.
ghrelin
ghrelin mimetics e.g.
anamorelin
ipamorelin
GH-Releasing Peptides (GHRPs) e.g.
alexamorelin
GHRP-6
hexarelin
pralmorelin (GHRP-2).
Additional prohibited growth factors:
Fibroblast Growth Factors (FGFs);
Hepatocyte Growth Factor (HGF);
Insulin-like Growth Factor-1 (IGF-1) and its analogues;
Mechano Growth Factors (MGFs);
Platelet-Derived Growth Factor (PDGF);
Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.
S3. Beta-2 Agonists
All beta-2 agonists, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Except:
Inhaled salbutamol (maximum 1600 micrograms over 24 hours);
Inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours); and
Inhaled salmeterol in accordance with the manufacturers’ recommended therapeutic regimen.
The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.
S4. Hormone and Metabolic Modulators
The following hormone and metabolic modulators are prohibited:
1. Aromatase inhibitors including, but not limited to:
4-androstene-3,6,17 trione (6-oxo)
aminoglutethimide
anastrozole
androsta-1,4,6-triene-3,17-dione (androstatrienedione)
exemestane
formestane
letrozole
testolactone.
2. Selective estrogen receptor modulators (SERMs) including, but not limited to:
raloxifene
tamoxifen
toremifene.
3. Other anti-estrogenic substances including, but not limited to:
clomiphene
cyclofenil
fulvestrant.
4. Agents modifying myostatin function(s) including, but not limited, to:
myostatin inhibitors.
5. Metabolic modulators:
Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists e.g. GW 1516
Insulins and insulin-mimetics
Meldonium
Trimetazidine
S5. Diuretics and Masking Agents
The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).
Including, but not limited to:
desmopressin
probenecid
plasma expanders e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol
acetazolamide
amiloride
bumetanide
canrenone
chlortalidone
etacrynic acid
furosemide
indapamide
metolazone
spironolactone
thiazides, e.g. bendroflumethiazide
chlorothiazide and hydrochlorothiazide
triamterene
vaptans, e.g. tolvaptan.
Except:
drospirenone
pamabrom
ophthalmic use of carbonic anhydrase inhibitors, e.g.
brinzolamide
dorzolamide
Local administration of felypressin in dental anaesthesia.
The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding unless the Athlete has an approved TUE for that substance in addition to the one granted for the diuretic or masking agent.
S6. Stimulants
All stimulants, including all optical isomers e.g. d- and l- where relevant, are prohibited.
Stimulants include:
a: Non-Specified Stimulants:
adrafinil
amfepramone
amfetamine
amfetaminil
amiphenazole
benfluorex
benzylpiperazine
bromantan
clobenzorex
cocaine
cropropamide
crotetamide
fencamine
fenetylline
fenfluramine
fenproporex
fonturacetam [4-phenylpiracetam (carphedon)]
furfenorex
mefenorex
mephentermine
mesocarb
metamfetamine (d-)
modafinil
norfenfluramine
phendimetrazine
p-methylamphetamine
phentermine
prenylamine
prolintane.
A stimulant not expressly listed in this section is a Specified Substance.
b: Specified Stimulants
Including, but not limited to:
benzfetamine
cathine**
cathinone and its analogues e.g. mephedrone, methedrone, α- pyrrolidinovalerophenone
dimethylamphetamine
ephedrine***
epinephrine**** (adrenaline)
etamivan
etilamfetamine
etilefrine
famprofazone
fenbutrazate
fencamfamin
heptaminol
hydroxyamfetamine (parahydroxyamphetamine)
isometheptene
levmetamfetamine
meclofenoxate
methylenedioxymethamphetamine
methylephedrine***
methylhexaneamine (dimethylpentylamine)
methylphenidate
nikethamide
norfenefrine
octopamine
oxilofrine (methylsynephrine)
pemoline
pentetrazol
phenethylamine and its derivatives;
phenmetrazine
phenpromethamine
propylhexedrine
pseudoephedrine*****
selegiline
sibutramine
strychnine
tenamfetamine (methylenedioxyamphetamine)
tuaminoheptane
and other substances with a similar chemical structure or similar biological effect(s). Except:
clonidine
Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2016 Monitoring Program*.
* Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradol and synephrine: These substances are included in the 2016 Monitoring Program, and are not considered Prohibited Substances. ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter. **** Epinephrine (adrenaline): Not prohibited in local administration e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.
S7. Narcotics
Prohibited:
buprenorphine
dextromoramide
diamorphine (heroin)
fentanyl and its derivatives
hydromorphone
methadone
morphine
oxycodone
oxymorphone
pentazocine
pethidine.
S8. Cannabinoids
Prohibited:
Natural, e.g. cannabis, hashish and marijuana, or synthetic delta 9-tetrahydrocannabinol (THC)
Cannabimimetics, e.g. “Spice”, JWH-018, JWH-073, HU-210.
S9. Glucocorticoids
All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.Hide
If a Substance or Method is not found, please verify with your Anti-Doping Organization to ensure that this Substance or Method is not prohibited as a related Substance or Method that falls under an existing category.
In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3.
http://list.wada-ama.org/prohibited-all-times/prohibited-substances/